SLN (Silence Therapeutics) Other Long Term Assets: $0.13 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLN Silence Therapeutics PLC SLN
47 GF Score
Price $14.10
GF Value $0.09
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Silence Therapeutics Other Long Term Assets?

Silence Therapeutics SLN +3.72% 47 Other Long Term Assets is $0.13 Mil as of Jun. 2026. GuruFocus rates SLN with a GF Score™ of 47/100 and a GF Value™ of $0.09 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Silence Therapeutics's other long-term assets for the quarter that ended in Jun. 2026 was $0.13 Mil.

Silence Therapeutics's quarterly other long-term assets declined from Dec. 2025 ($0.13 Mil) to Mar. 2026 ($0.13 Mil) but then stayed the same from Mar. 2026 ($0.13 Mil) to Jun. 2026 ($0.13 Mil).

Silence Therapeutics's annual other long-term assets declined from Dec. 2023 ($3.28 Mil) to Dec. 2024 ($3.23 Mil) and declined from Dec. 2024 ($3.23 Mil) to Dec. 2025 ($0.13 Mil).

Silence Therapeutics Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Other Long Term Assets Chart

Silence Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 3.28 3.23 0.13

Silence Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.91 0.40 0.13 0.13 0.13
SLN
47GF Score
Silence Therapeutics PLC SLN
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silence Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $0.13 Mil mean?
Silence Therapeutics (SLN) has a Other Long Term Assets of $0.13 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Silence Therapeutics and its competitors.
Is Silence Therapeutics' Other Long Term Assets too high?
Silence Therapeutics' current Other Long Term Assets is $0.13 Mil. Overall, Silence Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Other Long Term Assets compare to NAUT and CHRS?
Silence Therapeutics' Other Long Term Assets of $0.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current Other Long Term Assets is $0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.09, compared to a current price of $14.10 — trading 15561.1% above its estimated fair value. The current Other Long Term Assets is $0.13 Mil. Silence Therapeutics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Other Long Term Assets is $0.13 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $14.10 is trading 15561.1% above its estimated GF Value™ of $0.09. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Other Long Term Assets: $0.13 Mil
  • GF Value™: $0.09 vs. price of $14.10 (15561.1% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
47GF Score

Get the complete analysis for SLN

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.10
Price
$0.09
GF Value